Thirty percent of pulmonary arterial hypertension (PAH) patients experience depression or anxiety, according to a study that looked at patients’ psychological disorders, feelings of stress, and social support. The study, “Quality of life and psychological symptoms in patients with pulmonary hypertension,” was published in the journal Heart…
News
AIT Therapeutics has acquired a global, exclusive license from NitricGen for a new nitric oxide (NO) delivery system that may benefit newborns with pulmonary hypertension (PH). Under terms of the deal for the system, called eNOGenerator, AIT will pay NitricGen a total of $2 million in up-front, clinical and regulatory milestone payment.
Non-invasive Doppler echocardiography does as good a job of assessing high blood pressure in lung arteries as the current invasive standard of right heart catheterization, a pulmonary hypertension study suggests. And doctors can use the results from either method to predict PH patients’ outcomes, researchers said. The team published their findings in…
This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…
Bellerophon Therapeutics has enrolled more than half the 188 patients it is seeking for its ongoing Phase 3 clinical trial of INOpulse as a treatment for pulmonary arterial hypertension. The 50 percent enrollment mark is a milestone because it will trigger an interim analysis of the nitric oxide therapy’s results. Under…
Researchers offer new and additional evidence that a naturally occurring compound may be a valuable treatment for pulmonary hypertension. The factor, called tetrahydrobiopterin (BH4), had beneficial effects on both lung blood vessels and the heart in a rat model of the disease. Their work also supports findings from early stage…
Results of a Phase 1 clinical trial of Liquidia Technologies’ powder formulation of treprostinil for pulmonary hypertension were promising enough to advance it into Phase 3 trials, the company reports. The trial included 57 healthy volunteers who randomly received escalating doses of the therapy, LIQ861, ranging between 25 mcg and…
Interim data collected from a Japanese clinical setting demonstrates the post-marketing efficacy and safety of Volibris (Letairis, ambrisentan) for the treatment of patients with pulmonary arterial hypertension (PAH). Oral administration of the drug improved the mean pulmonary arterial pressure and pulmonary vascular resistance with a good safety profile. The…
Diagnosing and managing pulmonary hypertension in premature American infants with bronchopulmonary dysplasia vary a lot from doctor to doctor, a survey of 306 neonatologists indicates. The study, “Practices surrounding pulmonary hypertension and bronchopulmonary dysplasia amongst neonatologists caring for premature infants,” was published in the Journal of Perinatology.
Tenax Therapeutics plans to advance its lead compound, levosimendan, into a Phase 2 clinical trial to treat pulmonary hypertension (PH) associated with heart failure and preserved ejection fraction (PH-HFpEF) — a type of PH related to left heart disease. The company, based in Morrisville, North Carolina, aims to start…
Primary pulmonary hypertension (PH), age extremes (less than 6 months or older than 16 years), invasive interventions, and co-diagnoses with other severe diseases are all risk factors for mortality in children with PH who are in pediatric intensive care units, a new study shows. The study, “Multicenter…
Ubenimex, an oral dual-inhibitor developed by Eiger BioPharmaceuticals, has failed to demonstrate its effectiveness to treat pulmonary arterial hypertension (PAH) in the Phase 2 LIBERTY study. Initiated in 2016, the LIBERTY trial (NCT02664558) included 61 patients with diagnosed WHO Group 1 PAH across 45 clinical sites in…
